An experimental belly injection cut deep “organ-wrapping” fat by about 12% on magnetic resonance imaging in early human testing, while placebo patients gained fat.
Story Snapshot
- Magnetic resonance imaging showed a 12.01% average drop in visceral fat after CBL-514 injections, versus a 5.68% rise with placebo.
- Participants received lower-abdominal injections every three weeks for up to 12 weeks; scans were done four weeks after the last dose.
- Randomized Phase 2 trials support a treatment effect on abdominal fat compartments.
- A peer-reviewed Phase 2 study already showed significant loss of subcutaneous belly fat with CBL-514 versus placebo.
What the new finding actually measured
Fox News reported that two Phase 2 trials of CBL-514 found a 12.01% average reduction in visceral fat volume by magnetic resonance imaging four weeks after the last treatment, while the placebo group gained 5.68% over the same window. Visceral fat surrounds the liver, pancreas, and intestines. Doctors care about it because high levels tie to higher risk for diabetes and heart disease. Measuring visceral fat with magnetic resonance imaging, not a bathroom scale, gives a direct view inside the abdomen.
Trial volunteers received injections in the lower abdomen every three weeks for up to 12 weeks. Doses reached 600 milligrams in some participants, according to the report. The reported result focuses on the percent change in visceral fat volume from baseline. That is an imaging-based outcome. It does not equal weight loss. It tells us whether the fat inside the belly cavity got smaller relative to the start of the study over a short follow-up.
What earlier peer-reviewed data already proved
A published randomized, single-blind, placebo-controlled Phase 2 trial showed that CBL-514 reduced subcutaneous abdominal fat in the treated area. The study randomized 76 adults two-to-one to drug versus placebo. At four weeks, the drug group had a 312 milliliter greater reduction in subcutaneous fat volume versus placebo, and the difference was 277 milliliters at eight weeks. Both results reached strong statistical significance in the journal report. That peer-reviewed result backs the basic claim that CBL-514 can shrink fat where it is injected.
Clinical trial listings describe related Phase 2 programs with randomization and placebo control, including one with 75 enrolled and another with 107 enrolled, lending context to the development plan. The sponsor has also posted a protocol and pharmacokinetic materials that outline dosing, safety, and measurement methods for the class. Together, the record supports a consistent aim: reduce abdominal fat by injection and track changes with imaging.
Why visceral fat is the headline grabber
Visceral fat is not just a pinch on the waist. It is the deep depot that signals higher metabolic risk. Large lifestyle studies connect a 10% drop in visceral fat with better insulin resistance scores years later. Some cohorts link such a reduction with a lower risk of type 2 diabetes over time. That background explains why a 12% imaging drop draws attention. If a shot can target the depot that matters most for health, patients will ask about it, and doctors will want to see longer-term data.
NEW TREATMENT: An experimental injection called CBL-514 slashed dangerous visceral fat — the deep abdominal fat wrapped around internal organs — by 12% in early human trials, while patients on a placebo saw their visceral fat increase nearly 6%.
The drug works by selectively… pic.twitter.com/23PMe6LG62
— Fox News Health (@foxnewshealth) October 12, 2026
The new report sits beside a clear, peer-reviewed win on subcutaneous fat and extends the story into the visceral compartment. The magnetic resonance imaging method gives the claim more weight than a tape measure would. The timing also matters. Scans occurred four weeks after the final injection, which frames this as an early, on-therapy snapshot rather than a long-term maintenance result.
What prudent next steps look like
Medical common sense supports three quick asks. First, publish the full visceral-fat analysis with the protocol number, the sample size, the confidence intervals, and the statistical plan tied to the imaging endpoint. That allows doctors and regulators to judge the precision of the 12% figure. Second, run follow-up at six and twelve months to see if visceral fat stays down or rebounds, and to track safety in real time. Third, add metabolic outcomes that people care about: fasting insulin, glucose tolerance, and hemoglobin A1c.
American conservative values prize clarity, choice, and results. Patients deserve plain numbers that show what changed and for how long, not slogans. If CBL-514 keeps visceral fat down and improves metabolic markers without heavy side effects, it will earn its place by performance, not hype. If the effect fades, that truth should be just as clear. Either way, transparent data lets doctors advise patients wisely and lets families weigh cost, benefit, and risk in line with their own goals.
Sources:
clinicaltrials.gov, academic.oup.com, clareohealth.com, cdn.clinicaltrials.gov, fda.gov
